Switch to:
More From Other Websites
Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure Aug 27 2015
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data Aug 26 2015
Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
Medivation to Gain Global Rights to BioMarin's Talazoparib Aug 25 2015
BioMarin's Medivation Deal Boosts EPS Aug 25 2015
Two Bay Area drug companies cut half-billion-dollar cancer drug deal Aug 24 2015
Medivation Buying Breast-Cancer Drug From BioMarin Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
UBS Analysts Might've Found Another BioMarin Catalyst Aug 21 2015
BioMarin's Drisapersen Gets Rare Pediatric Disease Status Aug 20 2015


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK